HLS Therapeutics (TSE:HLS) Hits New 12-Month Low – Should You Sell?

HLS Therapeutics Inc. (TSE:HLS)’s stock price hit a new 52-week low on Thursday . The company traded as low as C$3.78 and last traded at C$3.77, with a volume of 287090 shares. The stock had previously closed at C$3.98.

Analyst Ratings Changes

Separately, Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of C$6.00.

HLS Therapeutics Trading Down 2.8%

The firm has a fifty day moving average of C$4.24 and a two-hundred day moving average of C$4.42. The company has a market cap of C$121.03 million, a PE ratio of -12.09 and a beta of -0.18. The company has a current ratio of 1.00, a quick ratio of 1.01 and a debt-to-equity ratio of 75.00.

HLS Therapeutics (TSE:HLS) last released its quarterly earnings data on Wednesday, August 12th. The company reported C($0.03) EPS for the quarter. The business had revenue of C$14.67 million for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. During the same quarter in the previous year, the business posted ($0.09) earnings per share. As a group, sell-side analysts predict that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.